As digital-first healthcare pathways continue to evolve across Europe, pharmaceutical companies face a critical question: how can they responsibly support patient access while navigating complex regulatory environments and changing patient expectations? Our latest POV, explores the rise of Direct-to-Disease (DTD) models and how digital ecosystems are reshaping the way patients discover, access, and engage with care.
Drawing on insights from the rapidly growing GLP-1 market, Alberta Spreafico, SVP, Health Innovation, examines the shift toward digital-first access pathways, the emergence of telehealth, pharmacy and integrated-care ecosystems, and five strategic imperatives pharmaceutical companies should consider as they build compliant, patient-centered commercialization strategies. Learn how organizations can reduce friction across the care journey, strengthen patient engagement, and create sustainable value through ecosystem partnerships.
Download the POV to explore how Direct-to-Disease models could shape the future of healthcare commercialization in Europe.
Download the POV
Submit Your Details to Access the Content